NEW YORK (TheStreet) -- Shares of Isis Pharmaceuticals  (ISIS) fell 5.74% to $69.37 in afternoon trading Monday despite the company's announcement of positive Phase 1 trial data for its antisense drug ANGPTL3.

Healthy volunteers treated with ANGPTL3 achieved dose-dependent, statistically significant reductions in angiopoietin-like 3 (ANGPTL3) of up to 93% with a mean reduction of up to 84% from baseline.

"We are encouraged with the performance of ISIS-ANGPTL3 in healthy volunteers. Based on data from preclinical models of hyperlipidemia, we expect to see even greater lipid reductions in patients with hyperlipidemia than in healthy volunteers," said Richard Geary, senior vice president of Isis Pharmaceuticals, in a statement.

"In fact, in this study we observed that healthy volunteers with higher baseline lipid levels experienced larger lipid reductions than those with lower baseline lipid levels," he continued.

Insight from TheStreet's Research Team

Bob Lang commented on Isis Pharmaceuticals in a recent post on RealMoney.com. Here is what Lang had to say about the stock:

Isis Pharma (ISIS) is one of my favorite names for 2015 (I did a LEAPS webinar in January and this was on my buy list). ISIS had a sharp pullback in early February but just re-captured those old highs set in early January. The chart is constructive here, as resistance was penetrated, but then rejected at higher levels. It appears a consolidation is in order as the RSI stalled at 70 (see chart). A modest pullback toward $68-$70 would be an area to consider buying.

- Bob Lang, ' Taking Aim at 3 Healthcare Charts' originally published 3/23/2015 on RealMoney.com.

Want more information like this from Bob Lang BEFORE your stock moves? Learn more about RealMoney.com now.